
<!DOCTYPE html>

<html lang="en">
<head id="ctl00_ctl00_Head1"><meta charset="utf-8"/><meta content="width=device-width, initial-scale=1.0" name="viewport"/><meta content="IE=edge" http-equiv="X-UA-Compatible"/><title>
	Clinical Practice Guidelines : Anticoagulation therapy
</title><link href="/WorkArea/FrameworkUI/css/ektron.stylesheet.ashx?id=-1759591071+-300771134+1985268503" rel="stylesheet" type="text/css"/><link href="/TemplateAssets/stylesheets/bootstrap.css?v=180131" rel="stylesheet"/><link href="/TemplateAssets/stylesheets/bootstrap-rch.css?v=180131" rel="stylesheet"/><link href="/TemplateAssets/stylesheets/print.css?v=180131" media="print" rel="stylesheet" type="text/css"/>




<style>
		.rch-emg-top-banner {
		  background: #DA1A31;
		  margin: 0;
		  padding:10px; 
		  text-align: center;
		  font-weight: 400;
		  color: #fff;
		  font-size:13px;
		}
		
		.rch-emg-top-banner a {
			color: #fff;
		}
		
       </style>





<link href="/TemplateAssets/stylesheets/Open_Sans/fonts.css" rel="stylesheet" type="text/css"/><link href="/apple-touch-icon.png" rel="apple-touch-icon" sizes="180x180"/><link href="/favicon-32x32.png" rel="icon" sizes="32x32" type="image/png"/><link href="/favicon-16x16.png" rel="icon" sizes="16x16" type="image/png"/><link href="/manifest.json" rel="manifest"/><link color="#5bbad5" href="/safari-pinned-tab.svg" rel="mask-icon"/><meta content="#ffffff" name="theme-color"/>










</head>
<body class="rch-section-health-pro">
<form action="/clinicalguide/guideline_index/Anticoagulation_therapy/" id="aspnetForm" method="post">
<div class="aspNetHidden">


</div>

<div class="aspNetHidden">


</div>
<div>
<div>

<div class="ektron-ux-UITheme ux-app-siteApppageBuilder-setSizeTemplate">
</div>

</div>
</div>

<div class="container">
<div class="row hidden-xs" id="rch-header" style="height:116px">
<div class="col-xs-12">
<div id="rch-brand">
<a href="https://www.rch.org.au/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Home-icon');"><img alt="The Royal Children's Hospital Melbourne" class="rch-logo" src="https://www.rch.org.au/TemplateAssets/images/global/RCH-Brandmark.png"/></a>
<h1 class="rch-wai"><a href="https://www.rch.org.au/">The Royal Children's Hospital Melbourne</a></h1>
</div>
<ul id="rch-mini-nav">
<li><a href="https://www.rch.org.au/home/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Home-mini');"> Home</a></li>
<li><a href="https://www.rch.org.au/rch/about/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'About');">About</a></li>
<li><a href="http://blogs.rch.org.au/news/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'News');">News</a></li>
<li><a href="https://www.rch.org.au/careers/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Careers');">Careers</a></li>
<li><a href="https://shop.rch.org.au/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Shop');">Shop</a></li>
<li><a href="https://www.rch.org.au/rch/contact/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Contact');">Contact</a></li>
<li class="pull-right"><a class="quicklink-link" href="https://myrchportal.rch.org.au/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'My RCH Portal');">My RCH Portal</a></li>
</ul>

</div>
</div>
<div class="row" id="primary-nav">
<div class="col-sm-11 navbar navbar-default rch-main-nav">
<div class="navbar-header">
<button class="navbar-toggle" data-target=".navbar-collapse" data-toggle="collapse" type="button">
<span class="icon-bar"></span><span class="icon-bar"></span><span class="icon-bar"></span>
</button>
<a aria-label="Search the site" class="navbar-toggle navbar-search-button" href="https://www.rch.org.au/search/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Search-direct');" type="btn button">
<span class="glyphicon glyphicon-search"></span>
</a>
<a class="navbar-brand img-responsive" href="https://www.rch.org.au/"><img alt="RCH logo" src="https://www.rch.org.au/TemplateAssets/images/global/RCH_logo_navbar.png"/></a>
</div>
<div class="navbar-collapse collapse">
<ul class="nav nav-justified hidden-xs">
<li class="main-nav-4"><a href="https://www.rch.org.au/rch/health-professionals/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Health Professionals');">Health Professionals</a></li>
<li class="main-nav-1"><a href="https://www.rch.org.au/rch/patients-families/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Patients and Families');">Patients and Families</a></li>
<li class="main-nav-3"><a href="https://www.rch.org.au/rch/departments/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Departments and Services');">Departments and Services</a></li>
<li class="main-nav-5"><a href="https://www.rch.org.au/research/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Research');">Research</a></li>
</ul>
<ul class="nav visible-xs">
<li class="main-nav-1"><a href="https://www.rch.org.au/rch/health-professionals/"><span class="glyphicon glyphicon-chevron-right rch-orange" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Health Professionals');"></span> Health Professionals</a></li>
<li class="main-nav-2"><a href="https://www.rch.org.au/rch/departments/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Departments and Services');"><span class="glyphicon glyphicon-chevron-right rch-green"></span> Departments and Services</a></li>
<li class="main-nav-3"><a href="https://www.rch.org.au/rch/patients-families/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Patients and Families');"><span class="glyphicon glyphicon-chevron-right rch-blue"></span> Patients and Families</a></li>
<li class="main-nav-5"><a href="https://www.rch.org.au/research/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Research');"><span class="glyphicon glyphicon-chevron-right rch-yellow"></span> Research</a></li>
<li class="main-nav-compact"><a href="https://www.rch.org.au/home/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Home-mini');">Home</a></li>
<li class="main-nav-compact"><a href="https://www.rch.org.au/rch/about/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'About');">About</a></li>
<li class="main-nav-compact"><a href="http://blogs.rch.org.au/news/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'News');">News</a></li>
<li class="main-nav-compact"><a href="https://www.rch.org.au/careers/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Careers');">Careers</a></li>
<li class="main-nav-compact"><a href="https://www.rch.org.au/rch/support/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Support');">Support us</a></li>
<li class="main-nav-compact"><a href="https://www.rch.org.au/rch/contact/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Contact');">Contact</a></li>
</ul>
</div>
</div>
<div class="col-sm-1 hidden-xs" id="nav-search-icon">
<a aria-label="Open search form" href="https://www.rch.org.au" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Search-form');"><span class="glyphicon glyphicon-search"></span></a>
</div>
<div class="hidden-xs" id="search-field">
<div class="form-inline" role="form">
<div class="form-group">
<label class="sr-only" for="search-field">Search</label>
<div id="ctl00_ctl00_SearchPanelTop">





</div>
</div>
</div>
</div>
</div>
<div class="row hidden-xs" id="hero-row">
<div class="col-xs-12">
</div>
</div>
<div class="row" id="custom-row">
<div class="col-12">
</div>
</div>
<div class="row" id="title-row">
<div class="col-xs-12">
<div class="panel panel-default">
<div class="panel-body">
<h2>Clinical Practice Guidelines</h2>
<div class="hidden-md hidden-lg" id="titleblock-section-nav">
<div class="btn-group">
<button class="btn btn-primary dropdown-toggle" data-toggle="dropdown" type="button">
<span class="sr-only">Toggle section navigation</span>
<span class="visible-sm">
<span class="icon-bar"></span>
<span class="icon-bar"></span>
<span class="icon-bar"></span>
</span>
<span class="visible-xs">
<span class="icon-bar"></span>
<span class="icon-bar"></span>
<span class="icon-bar"></span>
</span>
</button>
<ul class="dropdown-menu">
<span class="nav-header">In this section</span>
<li>
<a href="https://www.rch.org.au/clinicalguide/About_Clinical_Practice_Guidelines/ ">
                                                About Clinical Practice Guidelines                                   
                                                </a>
</li>
<li>
<a href="https://www.rch.org.au/clinicalguide/ ">
                                                CPG index                                   
                                                </a>
</li>
<li>
<a href="https://www.rch.org.au/rchcpg/hospital_clinical_guideline_index/Nursing_guidelines_index/ ">
                                                Nursing Guidelines                                   
                                                </a>
</li>
<li>
<a href="https://www.rch.org.au/clinicalguide/about_rch_cpgs/Paediatric_Improvement_Collaborative/ ">
                                                Paediatric Improvement Collaborative                                   
                                                </a>
</li>
<li>
<a href="https://www.rch.org.au/clinicalguide/guideline_index/Parent_resources/ ">
                                                Parent resources                                   
                                                </a>
</li>
<li>
<a href="https://www.rch.org.au/clinicalguide/guideline_index/Retrieval_services/ ">
                                                Retrieval services                                   
                                                </a>
</li>
<li>
<a href="https://www.rch.org.au/clinicalguide/guideline_index/CPG_Committee_Calendar/ ">
                                                CPG Committee Calendar                                   
                                                </a>
</li>
<li>
<a href="https://www.rch.org.au/clinicalguide/about_rch_cpgs/CPG_information/ ">
                                                CPG information                                   
                                                </a>
</li>
<li>
<a href="https://www.rch.org.au/clinicalguide/about_rch_cpgs/Other_resources/ ">
                                                Other resources                                   
                                                </a>
</li>
<li>
<a href="https://www.rch.org.au/clinicalguide/forms/feedback/ ">
                                                CPG feedback                                   
                                                </a>
</li>
</ul>
</div>
</div>
</div>
</div>
<span class="breadcrumb hidden-xs">
<span id="ctl00_ctl00_rchFolderBreadCrumb"><a href="https://www.rch.org.au/" target="_self" title="The Royal Children&amp;#39;s Hospital">RCH</a>  &gt;  <a href="https://www.rch.org.au/rch/health-professionals/" target="_self" title="Health Professionals">Health Professionals</a>  &gt;  <a href="https://www.rch.org.au/clinicalguide/" target="_self" title="Clinical Practice Guidelines">Clinical Practice Guidelines</a>  &gt;  <a href="https://www.rch.org.au/clinicalguide/guideline_index/Anticoagulation_Therapy_Guidelines/" target="_self" title="&lt;p&gt;&lt;br/&gt;&lt;/p&gt;">Anticoagulation therapy</a></span>
</span>
</div>
</div>
<div class="row" id="content-row">

<div class="col-md-2 hidden-xs hidden-sm hidden-print" id="rch-secondary" role="complementary">
<p class="nav-header">In this section</p>
<ul class="nav sm sm-vertical" id="rch-sidenav">
<li>
<a class="" href="https://www.rch.org.au/clinicalguide/About_Clinical_Practice_Guidelines/ ">About Clinical Practice Guidelines</a>
</li>
<li>
<a class="" href="https://www.rch.org.au/clinicalguide/ ">CPG index</a>
</li>
<li>
<a class="" href="https://www.rch.org.au/rchcpg/hospital_clinical_guideline_index/Nursing_guidelines_index/ ">Nursing Guidelines</a>
</li>
<li>
<a class="" href="https://www.rch.org.au/clinicalguide/about_rch_cpgs/Paediatric_Improvement_Collaborative/ ">Paediatric Improvement Collaborative</a>
</li>
<li>
<a class="" href="https://www.rch.org.au/clinicalguide/guideline_index/Parent_resources/ ">Parent resources</a>
</li>
<li>
<a class="" href="https://www.rch.org.au/clinicalguide/guideline_index/Retrieval_services/ ">Retrieval services</a>
</li>
<li>
<a class="" href="https://www.rch.org.au/clinicalguide/guideline_index/CPG_Committee_Calendar/ ">CPG Committee Calendar</a>
</li>
<li>
<a class="" href="https://www.rch.org.au/clinicalguide/about_rch_cpgs/CPG_information/ ">CPG information</a>
</li>
<li>
<a class="" href="https://www.rch.org.au/clinicalguide/about_rch_cpgs/Other_resources/ ">Other resources</a>
</li>
<li>
<a class="" href="https://www.rch.org.au/clinicalguide/forms/feedback/ ">CPG feedback</a>
</li>
</ul>
</div>
<div class="col-md-10" id="rch-primary">
<div class="row visible-print" id="print-header" style="margin-left: 0; margin-right: 0;">
<div class="col-xs-9">
<h1>Anticoagulation therapy</h1>
</div>
<div class="col-xs-3">
<img alt="RCH Logo" class="pull-right img-responsive" src="https://www.rch.org.au/TemplateAssets/images/global/RCH-Master-500-000.png" style="margin:20px;" width="140"/>
</div>
</div>
<div>
<h1 class="hidden-print">Anticoagulation therapy</h1>
<span id="ctl00_ctl00_plhContent_plhContentBody_lblErrorMessage"></span>
<div class="" id="ctl00_ctl00_plhContent_plhContentBody_DropZone1_uxUpdatePanel">
<div data-ux-pagebuilder="DropZone" id="ctl00_ctl00_plhContent_plhContentBody_DropZone1_uxDropZone">
<div data-ux-pagebuilder="Column" style="width:100%">
<ul role="presentation">
<li role="presentation">
<div id="ctl00_ctl00_plhContent_plhContentBody_DropZone1_uxColumnDisplay_ctl00_uxControlColumn_ctl00_uxWidgetHost_uxUpdatePanel">
<div data-ux-pagebuilder="Widget">
<div class="widgetBody">
<div id="ctl00_ctl00_plhContent_plhContentBody_DropZone1_uxColumnDisplay_ctl00_uxControlColumn_ctl00_uxWidgetHost_uxWidgetHost_widget_CB">
<p>This page contains Clinical Practice Guidelines for the  administration of Standard Heparin infusions, <strong>systemic lytic therapy</strong> and  <strong>the management of a blocked central venous access device</strong>. <br/>
  In addition, the Clinical Haematology department has  developed guidelines to support <strong><a href="https://www.rch.org.au/haematology/anticoagulaton_service/Warfarin_Guidelines_for_Clinicians/" title="clinician’s management of warfarin">clinician’s management of warfarin</a></strong> and<strong> <a href="https://www.rch.org.au/haematology/anticoagulaton_service/clexane-guidelines/" title="low  molecular weight heparin (Clexane)">low  molecular weight heparin (Clexane)</a></strong>. These can be accessed from the department’s  webpage, or via the links below</p>
<h2>Unfractionated Heparin (UFH)</h2>
<p>The following are guidelines for the  commencement and maintenance of <strong>Unfractionated Heparin (UFH) infusions</strong>, also  known as Standard Heparin. It may be necessary to modify this protocol  according to individual patient requirements. Outside of Rosella and Koala, the  Clinical Haematology Department should be consulted before commencing a UFH  infusion </p>
<h2>Prescribing and administering UFH </h2>
<p>At RCH we only administer UFH by intravenous route. This guideline applies to the intravenous route only. UFH is compatible with 5% Dextrose and 0.9% NaCl</p>
<p><strong>Intravenous orders for UFH must state ALL of the following:</strong></p>
<ol type="a"><li>Total Dose (in units) of UFH in a prepared syringe. No abbreviation for units will be accepted</li><li>Dose (in units) to be infused per kilogram per hour (eg 20 units/kg/hour)</li><li>Volume (mL) to be infused per hour. </li><li>Individualised Target APTT range
    <ol><li>Obtain baseline FBE, APTT, INR, Creatinine and renal function.</li><li>Any patient with a low platelet count or an abnormal APTT or INR should be discussed with a Haematologist prior to starting UFH.</li><li>Three concentrations of UFH infusions are used across RCH: </li></ol></li><li>1000 units in 50 mL (for patients &lt;10 kg)</li><li>5000 units in 50 mL (for patients &gt;10 kg and &lt;40 kg)</li><li>10,000 units in 50 mL (for patients &gt;40 kg) </li></ol>
<p>NB <em>Patients that are fluid restricted may require more concentrated UFH solutions than that recommended based on weight. If this is necessary, increased vigilance is required and a Clinical Haematology consult is highly recommended</em>.</p>
<ol start="4"><li>Preparing an UFH syringe or bag
    <ol type="a"><li>IV orders should state the total dose (units), dose to be administered (units per kilogram per hour) and the volume (mL per hour) to be infused. If any of these details are missing, the prescribing doctor needs to rechart the order</li></ol></li></ol>
<p>                b.   Draw up required units of heparin and volume of diluent  </p>
<ol start="5"><li>Recommended therapeutic doses.  Patients with renal failure will require modified doses and should be discussed with Clinical Haematology.<span style="line-height: 1.5em;"> </span></li></ol>
<p><strong></strong></p>
<h3><strong>Table 1. Recommended age-related UFH dose to commence therapeutic anticoagulation</strong><span style="line-height: 1.5em; color: rgb(72, 85, 96); font-size: 13px;"> </span></h3>
<table class="table table-striped table-bordered table-hover" dropzone="copy">
<tbody>
<tr>
<td style="cursor: default;" valign="top" width="123"><p> </p>
</td>
<td style="cursor: default;" valign="top" width="151"><p><strong>&lt;1   year</strong></p>
</td>
<td style="cursor: default;" valign="top" width="151"><p><strong>&gt;1   year</strong></p>
</td>
<td style="cursor: default;" valign="top" width="151"><p><strong>16   years</strong></p>
</td>
</tr>
<tr>
<td style="cursor: default;" valign="top" width="123"><p><strong>Maintenance</strong></p>
</td>
<td style="cursor: default;" valign="top" width="151"><p>25 units/kg/hour</p>
</td>
<td style="cursor: default;" valign="top" width="151"><p>20 units/kg/hour</p>
</td>
<td style="cursor: default;" valign="top" width="151"><p>18 units/kg/hr</p><p>NB For patients weighing &lt;83 kg, max commencement rate = 1500 units/hr</p>
</td>
</tr>
</tbody>
</table>
<ol start="6"><li>Bolus doses of UFH on commencement of therapy are NOT recommended unless specifically requested by the Clinical Haematology team</li><li>Patients should have a dedicated line for UFH infusions. The infusion should not be </li></ol>
<p>       stopped or interrupted for other medication.</p>
<ol start="8"><li>Due to the significant risk for errors in drug calculation, infusion preparation and  </li></ol>
<p>       programing infusion pumps when commencing UFH infusions, careful checking</p>
<p>       procedures are required, including double checking at the patient bedside.<br/><span style="line-height: 1.5em;"> </span></p>
<table class="table table-striped table-bordered table-hover" dropzone="copy">
<tbody>
<tr>
<td bgcolor="white" height="54" style="cursor: default;" width="476"><p>    Patient Weight  x      Dose Required  (units/kg/hr) / Heparin concentration (units/mL) <span style="line-height: 1.5em;"> = mLs/hour to be</span> infused</p>
</td>
</tr>
</tbody>
</table>
<p>9.   Flow rate (mL per hour) will vary according to weight.</p>
<h2> Figure 1. UFH flow rate calculation</h2>
<p>The table below provides examples of UFH calculations based upon patient weight. All dose calculations are based upon age-appropriate UFH units/kg recommended to achieve therapeutic anticoagulation.  
</p>
<p><strong></strong></p>
<h3><strong>Table 2. Examples of UFH infusion calculations based on weight and units/kg/hr required</strong></h3>
<strong></strong><p> </p>
<table class="table table-striped table-bordered table-hover" dropzone="copy">
<tbody>
<tr>
<td style="cursor: default;" valign="top" width="139"><p><strong>Patient   Weight</strong></p>
</td>
<td style="cursor: default;" valign="top" width="139"><p><strong>Units/kg/hr</strong></p>
</td>
<td style="cursor: default;" valign="top" width="139"><p><strong>UFH   units required/hour</strong></p>
</td>
<td valign="top" width="139"><p><strong>mL/hour</strong></p>
</td>
</tr>
<tr>
<td style="cursor: default;" valign="top" width="139"><p><strong>3</strong></p>
</td>
<td style="cursor: default;" valign="top" width="139"><p><strong>25</strong></p>
</td>
<td style="cursor: default;" valign="top" width="139"><p><strong>75</strong></p>
</td>
<td valign="top" width="139"><p><strong>3.75</strong></p>
</td>
</tr>
<tr>
<td style="cursor: default;" valign="top" width="139"><p><strong>5</strong></p>
</td>
<td style="cursor: default;" valign="top" width="139"><p><strong>25</strong></p>
</td>
<td style="cursor: default;" valign="top" width="139"><p><strong>125</strong></p>
</td>
<td valign="top" width="139"><p><strong>6.25</strong></p>
</td>
</tr>
<tr>
<td style="cursor: default;" valign="top" width="139"><p><strong>15</strong></p>
</td>
<td style="cursor: default;" valign="top" width="139"><p><strong>20</strong></p>
</td>
<td style="cursor: default;" valign="top" width="139"><p><strong>300</strong></p>
</td>
<td valign="top" width="139"><p><strong>3</strong></p>
</td>
</tr>
<tr>
<td style="cursor: default;" valign="top" width="139"><p><strong>20</strong></p>
</td>
<td style="cursor: default;" valign="top" width="139"><p><strong>20</strong></p>
</td>
<td style="cursor: default;" valign="top" width="139"><p><strong>400</strong></p>
</td>
<td style="cursor: default;" valign="top" width="139"><p><strong>4</strong></p>
</td>
</tr>
<tr>
<td style="cursor: default;" valign="top" width="139"><p><strong>30</strong></p>
</td>
<td style="cursor: default;" valign="top" width="139"><p><strong>20</strong></p>
</td>
<td style="cursor: default;" valign="top" width="139"><p><strong>600</strong></p>
</td>
<td style="cursor: default;" valign="top" width="139"><p><strong>6</strong></p>
</td>
</tr>
<tr>
<td style="cursor: default;" valign="top" width="139"><p><strong>50</strong></p>
</td>
<td style="cursor: default;" valign="top" width="139"><p><strong>20</strong></p>
</td>
<td style="cursor: default;" valign="top" width="139"><p><strong>1000</strong></p>
</td>
<td style="cursor: default;" valign="top" width="139"><p><strong>5</strong></p>
</td>
</tr>
<tr>
<td style="cursor: default;" valign="top" width="139"><p><strong>75</strong></p>
</td>
<td style="cursor: default;" valign="top" width="139"><p><strong>18</strong></p>
</td>
<td style="cursor: default;" valign="top" width="139"><p><strong>1350</strong></p>
</td>
<td style="cursor: default;" valign="top" width="139"><p><strong>6.75</strong></p>
</td>
</tr><tr><td style="cursor: default;"><strong>≥83</strong></td><td style="cursor: default;"><strong>Capped rate (units/hr)</strong></td><td style="cursor: default;"><strong> 1500</strong></td><td style="cursor: default;"><strong> 7.5</strong></td></tr>
</tbody>
</table>
<p>*maximum upper limit of 1500 units per hour starting dose breached by weight x 18 unit/kg/hr calculation</p>
<p><strong>Monitoring therapeutic UFH infusions</strong></p>
<p>UFH is monitored using the APTT assay. The table below summarises a UFH dosing nomogram based on the APTT result. APTT results across laboratories cannot be reliably compared.</p>
<p>In some clinical scenarios, the APTT may not be accurate, and an anti-Xa assay may be used. Within adult based studies, an anti-Xa assay of 0.35-0.7 units/mL equates to a therapeutic UFH dose. Consultation with the Clinical Haematology unit is recommended in such scenarios.</p>
<ol><li>Obtain venous blood sample for an APTT assay 6 hours post UFH commencement, or as directed by the Clinical Haematology department. In most instances, it is not necessary to wake patients overnight for UFH monitoring tests. This checking of the APTT is to ensure patients are not supra-therapeutic. A UFH dose change may not be required. </li><li>Adjust UFH infusion rate to maintain APTT within the range determined as optimal for that patient according to the Nomogram below. Clinical Haematology consultation is recommended to determine ongoing monitoring requirements. For most patients one APTT assay every 24 hours is sufficient. </li></ol>
<p><strong>If two unsuccessful attempts to obtain a venous APTT have occurred, contact the Clinical Haematology department before further attempts are made.</strong><span style="line-height: 1.5em;"> </span></p>
<h3>Table 3. Nomogram for adjusting UFH dose</h3>
<table class="table table-striped table-bordered table-hover" dropzone="copy">
<tbody>
<tr>
<td style="cursor: default;" valign="top" width="113"><p>APTT<span style="line-height: 1.5em;">(seconds)</span></p>
</td>
<td style="cursor: default;" valign="top" width="113"><p>BOLUS (units/kg) </p>
</td>
<td style="cursor: default;" valign="top" width="113"><p>Hold<span style="line-height: 1.5em;">(minutes)</span></p>
</td>
<td valign="top" width="113"><p>Rate change (units/hr)</p>
</td>
<td valign="top" width="113"><p>Repeat APTT</p>
</td>
</tr>
<tr>
<td style="cursor: default;" valign="top" width="113"><p>&lt;50</p>
</td>
<td style="cursor: default;" valign="top" width="113"><p>*</p>
</td>
<td style="cursor: default;" valign="top" width="113"><p>0</p>
</td>
<td valign="top" width="113"><p>Increase 20%</p>
</td>
<td valign="top" width="113"><p>4 hours</p>
</td>
</tr>
<tr>
<td style="cursor: default;" valign="top" width="113"><p>50-59</p>
</td>
<td style="cursor: default;" valign="top" width="113"><p>0</p>
</td>
<td style="cursor: default;" valign="top" width="113"><p>0</p>
</td>
<td valign="top" width="113"><p>Increase 10%</p>
</td>
<td style="cursor: default;" valign="top" width="113"><p>6 hours</p>
</td>
</tr>
<tr>
<td style="cursor: default;" valign="top" width="113"><p>60-85</p>
</td>
<td style="cursor: default;" valign="top" width="113"><p>0</p>
</td>
<td style="cursor: default;" valign="top" width="113"><p>0</p>
</td>
<td style="cursor: default;" valign="top" width="113"><p>No change</p>
</td>
<td style="cursor: default;" valign="top" width="113"><p>24 hours</p>
</td>
</tr>
<tr>
<td style="cursor: default;" valign="top" width="113"><p>86-95</p>
</td>
<td style="cursor: default;" valign="top" width="113"><p>0</p>
</td>
<td style="cursor: default;" valign="top" width="113"><p>0</p>
</td>
<td style="cursor: default;" valign="top" width="113"><p>Reduce 10%</p>
</td>
<td style="cursor: default;" valign="top" width="113"><p>6 hours</p>
</td>
</tr>
<tr>
<td style="cursor: default;" valign="top" width="113"><p>96-120</p>
</td>
<td style="cursor: default;" valign="top" width="113"><p>0</p>
</td>
<td style="cursor: default;" valign="top" width="113"><p>30</p>
</td>
<td style="cursor: default;" valign="top" width="113"><p>Reduce 10%</p>
</td>
<td valign="top" width="113"><p>6 hours</p>
</td>
</tr>
<tr>
<td style="cursor: default;" valign="top" width="113"><p>&gt;120</p>
</td>
<td style="cursor: default;" valign="top" width="113"><p>0</p>
</td>
<td style="cursor: default;" valign="top" width="113"><p>60</p>
</td>
<td style="cursor: default;" valign="top" width="113"><p>Reduce 15%</p>
</td>
<td style="cursor: default;" valign="top" width="113"><p>6 hours</p>
</td>
</tr>
</tbody>
</table>
<p><em>*Bolus may be appropriate depending on clinical situation and perceived bleeding risk. Consult the Clinical Haematology department.  </em></p>
<p>3. The rate changes suggested in the table above are to be calculated as a percentage of  </p>
<p>       the total infusion, that is, in units/kg/hour. </p>
<p>4. Do NOT turn off UFH infusion prior to collecting an APTT or anti-Xa assay. </p>
<p>5. APTT blood samples should NOT be drawn from the same line (or limb) as the UFH </p>
<p>    infusion. If this cannot be avoided, a minimum discard volume of 5 mL should be collected </p>
<p>    prior to collecting the APTT or Anti-Xa sample. </p>
<p>6.  Coagulation tubes must be filled exactly to the specified mark to avoid erroneous results.</p>
<p>7.  Twice weekly FBEs, (platelet count) and renal function are required. If there is an abrupt decrease in platelet count, (eg 50%) consult the Clinical Haematology department. </p>
<p>8. The duration of UFH therapy is dependent upon the primary problem. Please consult the Clinical Haematology department for guidelines. </p>
<p><strong>Precautions</strong></p>
<ol><li>Avoid IM injections and arterial stabs during anticoagulant therapy. When such procedures are clinically necessary, ensure adequate external pressure is applied post-procedure.</li><li>Lumbar punctures should not be performed while patients are on UFH therapy.</li><li>Avoid aspirin and other anti-platelet medications during UFH therapy.</li><li>UFH should be withheld prior to procedures. The timing of UFH cessation around procedures will vary depending upon the procedure to be performed and the patient's individual risk of bleeding and thrombosis. Clinical Haematology consultation is recommended in determining the timing of UFH cessation around procedures.<strong> </strong></li></ol>
<p><strong>Adverse Events</strong></p>
<p>The major adverse event potentially related to UFH infusion is bleeding. The reported frequency of UFH-related major bleeding varies significantly, from major bleeding rates ranging from 0 to 24% of patients exposed to UFH. If a patient on UFH develops bleeding, cease UFH infusion and seek urgent Clinical Haematology consult. Heparin induced thrombocytopenia (HIT) is a potentially life-threatening UFH-related adverse event. In adults, the reported incidence ranges from 3-5%. In children, the incidence is likely much lower. Thrombocytopenia occurring in the setting of UFH therapy is likely to be secondary to patient's comorbidity. Screening for the possibility of HIT requires Clinical Haematology consultation. </p>
<p><strong>UFH Antidote</strong></p>
<p>If anticoagulation with UFH needs to be discontinued for clinical reasons, termination of the UFH infusion will usually suffice. If an immediate effect is required, consider administering protamine sulfate.  </p>
<p>Protamine is a medication that requires a high level of caution when being prescribed and administered. Outside of cardiac surgery and ICU, Clinical Haematology approval is required for the use of protamine – do not allow this to lead to delayed administration in the case of bleeding. Contact the appropriate senior person immediately. </p>
<p>Protamine sufhate neutralises UFH by virtue of its positive charge. Following IV administration, neutralisation occurs within 5 minutes. The dose of protamine sulfate is based on the amount of UFH received <strong>in the previous 2 hours</strong> as follows: </p>
<p><strong></strong></p>
<h3><strong>Table 4. Protamine dose for UFH reversal</strong><span style="line-height: 1.5em; color: rgb(72, 85, 96); font-size: 13px;"> </span></h3>
<table class="table table-striped table-bordered table-hover" dropzone="copy">
<tbody>
<tr>
<td style="cursor: default;" valign="top" width="246"><p><strong>Time   since Last  UFH Dose</strong></p>
</td>
<td style="cursor: default;" valign="top" width="302"><p><strong>Protamine   Dose (mg) per 100units UFH received</strong></p>
</td>
</tr>
<tr>
<td style="cursor: default;" valign="top" width="246"><p>&lt;30 min</p>
</td>
<td style="cursor: default;" valign="top" width="302"><p>1 mg</p>
</td>
</tr>
<tr>
<td style="cursor: default;" valign="top" width="246"><p>30-60 min</p>
</td>
<td style="cursor: default;" valign="top" width="302"><p>0.5-0.75 mg</p>
</td>
</tr>
<tr>
<td style="cursor: default;" valign="top" width="246"><p>60-120 min</p>
</td>
<td style="cursor: default;" valign="top" width="302"><p>0.375-0.5 mg</p>
</td>
</tr>
<tr>
<td style="cursor: default;" valign="top" width="246"><p>&gt;120 min</p>
</td>
<td style="cursor: default;" valign="top" width="302"><p>0.25-0.375 mg</p>
</td>
</tr>
</tbody>
</table>
<p>The maximum dose of protamine sulfate, regardless of the amount of UFH received is 50 mg except for reversal of UFH following cardiopulmonary bypass. Protamine sulfate is usually administered in a concentration of 10 mg/mL at a rate not to exceed 5 mg/minute. If administered too quickly, protamine sulfate may cause cardiovascular collapse. Patients with known hypersensitivity reactions to fish, and those who have received protamine- containing insulin or previous protamine therapy may be at risk of hypersensitivity reactions to protamine sulfate. Obtain blood for PT and APTT 15 min after the administration of protamine sulfate. <span style="line-height: 1.5em;"> </span></p>
<h2><a id="Systemic_Lytic_Therapy" name="Systemic_Lytic_Therapy" title="Systemic_Lytic_Therapy"></a>Systemic lytic therapy </h2>
<p>This is a guideline for the use of systemic lytic  therapy. There is no robust data to support the use of local lytic therapy in  infants and children <strong></strong><em>except for line  blockages. </em>Administration of systemic  lytic therapy within the RCH requires involvement of the Clinical Haematology  department.<em style="line-height: 1.5em;"> </em></p>
<h3>Indications</h3>
<ul><li>Massive pulmonary embolism </li><li>Pulmonary embolism not responding to heparin</li><li>Arterial occlusions threatening organ or limb  viability</li><li>Potential for acute, extensive DVT threatening organ  or limb viability.<span style="line-height: 1.5em;"> </span></li></ul>
<h3>Contraindications</h3>
<ul><li>Active bleeding</li><li>Significant potential for serious local bleeding</li><li>General surgery within the previous 10 days</li><li>Neurosurgery within the previous 3 weeks</li><li>AV malformations</li><li>Recent significant trauma.<span style="line-height: 1.5em;"> </span></li></ul>
<h3>Preparation  for infusion</h3>
<ul><li>Obtain patient weight, FBE, INR/PT, APTT and  fibrinogen. Platelet count must be &gt;100. Fibrinogen must be ³ 1.0. Administer FFP infusion 20ml/kg if clinically indicated. Consider  administering Vitamin K if the patient could be deficient.</li><li>Consider appropriate staffing requirements are in place to monitor  infusion.</li><li> Ensure adequate venous access to:</li><li>infuse lytic  therapy, and </li><li>obtain blood  specimens during infusion.<span style="line-height: 1.5em;"> </span></li><li>Establish heparin infusion of 10 units/kg/hour to be administered  continuously throughout lytic infusion (see Standard Heparin Infusion Clinical  Practice Guideline). If possible heparin should be administered for 6 hours  prior to lysis as this may reduce the likelihood of thrombus progression.  Concomitant low molecular weight heparin therapy has been reported, however the  limited reversibility of this agent makes it a less-preferred option compared  to standard heparin.<span style="line-height: 1.5em;"> </span></li><li>tPA is the preferred lytic agent for use in children due to limited  evidence regarding reduced immunogenicity, improved <em>in vitro </em>clot lysis, and fibrin specificity compared to urokinase  and streptokinase. In some limited instances, streptokinase may be selected in  preference to tPA. </li></ul>
<p><strong>DO NOT </strong>use Streptokinase if the patient has previously been exposed to  streptokinase. Premedicate with paracetamol and/or promethazine due to  potential for allergic reactions.</p>
<p>6.   Administer lytic therapy as per following guidelines:</p>
<table class="table table-striped table-bordered table-hover" dropzone="copy">
<tbody>
<tr>
<td style="cursor: default;" valign="top" width="113"><p> </p>
</td>
<td style="cursor: default;" valign="top" width="151"><p><strong>Loading    dose</strong></p>
</td>
<td style="cursor: default;" valign="top" width="161"><p><strong>Infusion    dose</strong></p>
</td>
<td valign="top" width="113"><p><strong>Maximum    loading dose</strong></p>
</td>
</tr>
<tr>
<td style="cursor: default;" valign="top" width="113"><p><strong>TPA</strong></p>
</td>
<td style="cursor: default;" valign="top" width="151"><p>No*</p>
</td>
<td style="cursor: default;" valign="top" width="161"><p>0.5 mg/kg/hour over 6 hours.</p>
</td>
<td valign="top" width="113"><p>n/a</p>
</td>
</tr>
<tr>
<td style="cursor: default;" valign="top" width="113"><p><strong>Streptokinase</strong></p>
<p><strong> </strong></p>
</td>
<td style="cursor: default;" valign="top" width="151"><p>2000 units/kg over 10 minutes</p>
</td>
<td style="cursor: default;" valign="top" width="161"><p>1000 units/kg/hour over 6 hours</p>
</td>
<td valign="top" width="113"><p>250,000 units</p>
</td>
</tr>
</tbody>
</table>
<p>*occasionally "front-loaded" tPA therapy is indicated. The  Clinical Haematology department will discuss this option with clinical teams as  indicated. </p>
<ul><li>Throughout infusion monitor:   -  pulse &amp; BP hourly</li><li>Inspect all puncture sites hourly during infusion and for 4 hours post  infusion</li><li>Check Fibrinogen 3 hours into infusion and at completion</li><li>If any signs of bleeding and/or bruising occur– cease tPA and Heparin infusions  and seek urgent Clinical Haematology consult</li><li>If treating a peripheral artery thrombosis, observe limb hourly for pulse,  colour, temperature and capillary return</li><li>Cease lytic therapy at 6 hours. Increase heparin to 20 units/kg/hour (no  bolus). Arrange Clinical Haematology review to determine response or need for  further lysis<span style="line-height: 1.5em;"> </span></li></ul>
<h3>Treatment of bleeding secondary to thrombolytic therapy</h3>
<p>Based upon case series reports and cohort studies, 30-50%  of patients receiving systemic lytic therapy will experience a bleeding event,  with approximately 11-40% of patients requiring red blood cell transfusion. An  increased likelihood of bleeding is associated with a prolonged lytic therapy  infusion. Minor bleeding usually presents as oozing from a wound or puncture  site. Major bleeding is defined as bleeding into a body cavity (intracranial,  retroperitoneal, thoracic) or external bleeding requiring transfusion.</p>
<p>If bleeding occurs, cease tPA and heparin infusions  and seek an urgent Clinical Haematology review. Treatment with local pressure  is usually sufficient management of bleeding from wound or puncture sites.  Cryoprecipitate, antifibrinolytics and blood products may be indicated for the  management of major bleeding.<span style="line-height: 1.5em;"> </span></p>
<h3>Precautions</h3>
<ul><li>No IM injections during lytic therapy</li><li>Minimize patient handling during infusion</li><li>Avoid concurrent use of warfarin and antiplatelet agents</li><li>Delay any invasive procedures such as urinary catheterization, re-siting  venous/arterial access, or perform such procedures pre-lytic infusion</li><li>One author has suggested lytic therapy is contraindicated in infants  &lt;32 weeks gestation, despite anecdotal reports existing regarding the  successful use of lytic therapy in such infants. Decision making regarding the  risk: benefit of lytic therapy should be made on an individualised basis <span style="line-height: 1.5em;"> </span></li></ul>
<h3>Local</h3>
<p><strong>Consultation  with the Clinical Haematology Department is required.</strong> Contact can be made on ext. 52605 during office hours or page the  on-call Haematologist through RCH switchboard after-hours.</p>
<h2>RCH specific information</h2>
<p>Consultation with the Clinical Haematology Department is required for therapeutic infusions outside of the Paediatric Intensive Care Unit and Cardiac Unit. Contact can be made by paging the Inpatient Clinical Haematology Registrar on pager 5030 during office hours or page the on-call Haematologist through RCH switchboard after hours.</p>
<p><strong>References</strong></p>
<p>1. Monagle P, Chan A, Goldenberg N, Ichord R, Journeycake J, Nowak-Gottl U, Vesely S. Antithrombotic therapy in neonates and children: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-based clinical practice guidelines. Chest. 2012;141:e737-e801S.</p>
<p>2. Newall F, Ignjatovic V, Johnston L, Monagle P. Unfractionated heparin therapy in infants and children. Pediatrics. 2009b;123:e510-e8.</p>
<p>3. Monagle P, Barnes C, Ignjatovic V, Furmedge J, Newall F, Chan A, DeRosa L, Hamilton S, Ragg P, Robinson S, Auldist A, Crock C, Rowlands S. Developmental haemostasis: Impact for clinical haemostasis laboratories. Thrombosis and Haemostasis. 2006;95:362-72.</p>
<p>4. Monagle P, Newall F. Anticoagulation in Children. Thrombosis Research. 2012;130:124-46.</p>
<p>5. Newall F, Ignjatovic V, Johnston L, Summerhayes R, Lane G, Cranswick N, Monagle P. Age is a determinant factor for measures of concentration and effect in children requiring unfractionated heparin. Thrombosis and Haemostasis. 2010a;103:1085-90.</p>
<p>6. Newall F, Ignjatovic V, Johnston L, Summerhayes R, Lane G, Cranswick N, Monagle P. Clinical use of unfractionated heparin therapy in children: time for change? British Journal of Haematology. 2010;150: 674-678. </p>
<p>7. McDonald M, Hathaway W. Anticoagulation therapy by continuous heparinization in newborn and older infants. The Journal of Pediatrics 1982;101(3):451-457.</p>
<p>8. Andrew M, Marzinotto V, Massicotte P, Blanchette V, Ginsberg J, Brill-Edwards P, et al. Heparin therapy in pediatric patients: a prospective cohort study. Pediatric Research 1994;35(1):78-83.</p>
<p>9. Chan A, Berry L, Monagle P, Andrew M. Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential. Thrombosis and Haemostasis 2002;87:606-13.</p>
<p>10. Kuhle S, Eulmesekian P, Kavanagh B, Massicotte P, Vegh P, Mitchell L. A clinically significant incidence of bleeding in critically ill children receiving therapeutic doses of unfractionated heparin: a prospective cohort study. Haematologica 2007;92(2):244-47.</p>
<p>11. Kuhle S, Eulmesekian P, Kavanagh B, Massicotte P, Vegh P, Lau A, et al. Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children. Haematologica 2007;92(4):554-557.</p>
<p>12. Ignjatovic V, Summerhayes R, Than J, Gan A, Monagle P. Therapeutic range for unfractionated heparin therapy: age-related differences in response in children. Journal of Thrombosis and Haemostasis 2006;4(10):2280-2282.</p>
<p>13. Ignjatovic V, Furmedge J, Newall F, Chan A, Berry L, Fong C, et al. Age-related differences in heparin response. Thrombosis Research 2006;118(6):741-45.</p>
<p>14. Ignjatovic V, Summerhayes R, Gan A, Than J, Chan A, Cochrane A, et al. Monitoring unfractionated heparin (UFH) therapy: which anti factor Xa assay is appropriate? Thrombosis Research 2007;120(3):347-351.</p>
<p>15. Newall F, Barnes C, Ignjatovic V, Monagle P. Heparin-induced thrombocytopaenia in children. Journal of Paediatrics and Child Health 2003;39(4):289-92.</p>
<p>16. Infant deaths due to Heparin overdose: time for a concerted action on prevention. Monagle P, Studdert D, Newall F. Journal of Paediatrics and Child Health. 48(5):380–381. 2012.</p>
</div>
<span id="ctl00_ctl00_plhContent_plhContentBody_DropZone1_uxColumnDisplay_ctl00_uxControlColumn_ctl00_uxWidgetHost_uxWidgetHost_widget_errorLb"></span>
</div>
</div>
</div>
</li>
</ul>
</div>
</div>
</div>
<div>
<div id="ctl00_ctl00_plhContent_plhContentBody_cbCpgDis">

</div>
</div>

</div>
<div>
<div id="ctl00_ctl00_plhContent_plhRightCol_ContentBlock1">

</div>
</div>
<span id="ctl00_ctl00_lblErrorMessage"></span>
</div>
</div>
<style>

            

         footer #footer-Wurundjeri {
            background-color: #a2260b;
            color:white;
            font-size:16px;
         }

          footer #footer-row1 {
            background-color: none;
            }
                    
          footer #footer-Wurundjeri-text {
            background-color: none;
            }
                    
          footer #footer-row2 {
            background-color: none;
            }

           footer .footer_iocons1 {

                   display: block;
                   width: auto;
                    height: 35px;
            
            }

           footer .footer_iocons2 {

                   display: block;
                   width: auto;
                    height: 50px;
            
            }


       </style>
<footer>
<div class="row hidden-md hidden-sm hidden-xs" id="footer-Wurundjeri" style="background-color: #a2260b;padding-left: 0px;">
<div class="col-md-3 col-xs-12 social-icons" style="padding-left: 0px;">
<img alt="Wadja logo" class="img-responsive" src="https://www.rch.org.au/uploadedImages/Main/Content/rch/Wadja-footer-artwork-222x60.png">
</img></div>
<div class="col-md-9 col-xs-12" id="footer-Wurundjeri-text" style="margin-top:16px;">
<p>The Royal Children’s Hospital (RCH) acknowledges the traditional owners of the land on which the RCH is situated, the Wurundjeri people of the Kulin Nation, and we pay our respects to their Elders past and present.</p>
</div>
</div>
<div class="row visible-xs" style="background-color: #a2260b;padding-left: 0px;">
<div class="col-xs-12 social-icons" style="padding-left: 0px;padding-right: 0px;">
<img alt="Wadja logo" class="img-responsive" src="https://www.rch.org.au/uploadedImages/Main/Content/rch/Wadja-footer-artwork-390x60(1).png"/>
</div>
<div class="col-xs-12" style="margin-top:16px; color: white;font-size: 16px;}">
<p>The Royal Children’s Hospital (RCH) acknowledges the traditional owners of the land on which the RCH is situated, the Wurundjeri people of the Kulin Nation, and we pay our respects to their Elders past and present.</p>
</div>
</div>
<div class="row visible-sm" style="background-color: #a2260b;padding-left: 0px;">
<div class="col-sm-12 social-icons" style="padding-left: 0px;padding-right: 0px;">
<img alt="Wadja logo" class="img-responsive" src="https://www.rch.org.au/uploadedImages/Main/Content/rch/Wadja-footer-artwork-390x60(1).png"/>
</div>
<div class="col-sm-12" style="margin-top:16px; color: white;font-size: 16px;}">
<p>The Royal Children’s Hospital (RCH) acknowledges the traditional owners of the land on which the RCH is situated, the Wurundjeri people of the Kulin Nation, and we pay our respects to their Elders past and present.</p>
</div>
</div>
<div class="row visible-md" style="background-color: #a2260b;padding-left: 0px;">
<div class="col-md-3 social-icons" style="padding-left: 0px;padding-right: 0px;">
<img alt="Wadja logo" class="img-responsive" src="https://www.rch.org.au/uploadedImages/Main/Content/rch/Wadja-footer-222x94px.png"/>
</div>
<div class="col-md-9" style="margin-top:16px; color: white;font-size: 16px;}">
<p>The Royal Children’s Hospital (RCH) acknowledges the traditional owners of the land on which the RCH is situated, the Wurundjeri people of the Kulin Nation, and we pay our respects to their Elders past and present.</p>
</div>
</div>
<br/><br/>
<div class="row" id="footer-row1" style="background-color:white">
<div class="col-sm-6 col-xs-12 social-icons">
<a href="https://www.facebook.com/rchmelbourne" onclick="ga('rchTracker.send', 'event', 'social', 'click', 'Facebook');" title="Facebook">
<i class="fa fa-facebook-square" style="color:#87946B;font-size:50px;"></i>
</a>
<a href="https://www.instagram.com/rchmelbourne/" onclick="ga('rchTracker.send', 'event', 'social', 'click', 'Instagram');" title="Instagram">
<i class="fa fa-instagram" style="color:#87946B;font-size:50px;"></i>
</a>

<a href="https://www.linkedin.com/company/8333989/" onclick="ga('rchTracker.send', 'event', 'social', 'click', 'LinkedIn');" title="LinkedIn">
<i class="fa fa-linkedin-square" style="color:#87946B;font-size:50px;"></i>
</a>
<a href="https://www.youtube.com/@RCHMelb/videos" onclick="ga('rchTracker.send', 'event', 'social', 'click', 'YouTube');" title="YouTube">
<i class="fa fa-youtube-square" style="color:#87946B;font-size:50px;"></i>
</a>
</div>
<div class="col-sm-6 col-xs-12" id="pig-and-interpreter">
<a href="https://www.rch.org.au/info/az_guide/Interpreter_Services/" onclick="ga('rchTracker.send', 'event', 'footer', 'click', 'Interpreter');" title="Interpreter Services">
<img alt="Interpreter Services" id="footer-interpreter-icon" src="https://www.rch.org.au/uploadedImages/Main/Content/rch/RCH-Interpreter-GumGreen.svg" style="height:50px"/>
</a>
<a href="https://www.rch.org.au/rch/support/" onclick="ga('rchTracker.send', 'event', 'footer', 'click', 'Support us');" title="Support us">
<img alt="Support us" id="footer-support-us" src="https://www.rch.org.au/uploadedImages/Main/Content/rch/RCH-Support-us-GumGreen.svg" style="height:50px"/></a>
</div>
</div>
<div class="row" id="footer-row2" style="background-color:white">
<div class="col-sm-6">
<div class="rch-footer-company" itemscope="" itemtype="http://schema.org/Organization">
<h3 itemprop="name">The Royal Children's Hospital Melbourne</h3>
<p itemprop="telephone" style="margin-bottom: 0px;">Telephone +61 3 9345 5522</p>
<p itemprop="address" itemscope="" itemtype="http://schema.org/PostalAddress"><span itemprop="streetAddress">50 Flemington Road Parkville</span> <span itemprop="addressLocality">Victoria <span itemprop="postalCode">3052</span> Australia</span></p>
</div>
</div>
<div class="rch-footer-company">
<div class="rch-footer-company">
<p class="footertmpright pppp"><a href="https://www.rch.org.au/rch/departments/" onclick="ga('rchTracker.send', 'event', 'footer', 'click', 'Site Map');">Site Map</a> | <a href="https://www.rch.org.au/rch/about/Copyright/" onclick="ga('rchTracker.send', 'event', 'footer', 'click', 'Copyright');">Copyright</a> | <a href="https://www.rch.org.au/rch/about/terms-and-conditions/" onclick="ga('rchTracker.send', 'event', 'footer', 'click', 'Terms and Conditions');">Terms and Conditions</a></p>

<p class="footer-grey footertmpright" style="margin-top:0;margin-bottom:0;">

<span id="Span1" style="display:none;"><br/></span>
<br/><span id="rch-footer-lastupdated"> </span>
</p>
</div>
</div>
</div>
<div class="row" id="footer-row3">
</div>
</footer>
</div>
</form>



</body>
</html>